News stories about Impax Laboratories (NASDAQ:IPXL) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Impax Laboratories earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 46.5052637891109 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

A number of brokerages recently commented on IPXL. BidaskClub lowered shares of Impax Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Cantor Fitzgerald reiterated a “buy” rating and issued a $25.00 price target on shares of Impax Laboratories in a research note on Monday, September 25th. Royal Bank Of Canada set a $17.00 price target on shares of Impax Laboratories and gave the company a “hold” rating in a research note on Thursday, August 10th. BTIG Research reiterated a “buy” rating and issued a $27.00 price target (up previously from $20.00) on shares of Impax Laboratories in a research note on Saturday, September 23rd. Finally, Zacks Investment Research upgraded shares of Impax Laboratories from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research note on Monday, October 16th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $19.60.

Impax Laboratories (IPXL) opened at $16.75 on Friday. Impax Laboratories has a 52-week low of $7.75 and a 52-week high of $25.70. The stock has a market cap of $1,240.00, a P/E ratio of 24.49, a price-to-earnings-growth ratio of 1.05 and a beta of 0.99. The company has a current ratio of 1.81, a quick ratio of 1.32 and a debt-to-equity ratio of 1.59.

Impax Laboratories (NASDAQ:IPXL) last announced its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.03. Impax Laboratories had a negative net margin of 56.59% and a positive return on equity of 9.06%. The firm had revenue of $206.40 million for the quarter, compared to analyst estimates of $208.38 million. During the same quarter in the prior year, the business posted $0.37 EPS. The business’s revenue was down 9.4% compared to the same quarter last year. sell-side analysts expect that Impax Laboratories will post 0.63 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/02/impax-laboratories-ipxl-getting-somewhat-positive-media-coverage-study-finds.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Insider Buying and Selling by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.